サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654350

静注用免疫グロブリン市場規模、シェア、動向分析レポート：用途別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 153 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
静注用免疫グロブリン市場規模、シェア、動向分析レポート：用途別、流通チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月22日
発行: Grand View Research
ページ情報: 英文 153 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

静注用免疫グロブリン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の静注用免疫グロブリン市場規模は、2025～2030年にかけてCAGR 7.2%で拡大し、2030年には210億5,000万米ドルに達すると推定されています。

免疫不全疾患の有病率の増加と静注用免疫グロブリン療法の採用が、予測期間中の市場成長を促進すると予想されます。また、免疫グロブリンの適応外使用の増加や医療セグメントへの投資が市場成長を後押しする要因となっています。さらに、出血性疾患の増加や高齢者の増加が産業成長の要因となっています。

原発性免疫不全症の治療や補充療法において皮下免疫グロブリン製剤の採用が増加していることは、今後7年間における市場の成長基盤になると予想されます。さらに、主要な市場参入企業は、世界の販売網を拡大するため、画期的な製品の導入に注力しています。例えば、Octapharma U.S.は、成人の皮膚筋炎として知られる免疫介在性炎症性疾患の治療に推奨される同社初の静注用免疫グロブリン製剤であるオクタガム10%のFDA認可を2021年7月に取得しました。

現在最終段階にあるCOVID-19パンデミックは、静注用免疫グロブリンの世界市場を押し上げると期待されています。例えばインドでは、Bharat BiotechがCOVID-19治療の可能性としてモノクローナル抗体を作製する研究を実施しています。科学産業研究評議会（CSIR）は、ニューミレニアムインド技術リーダーシップ戦略の一環として、このプロジェクトを承認しました。さらに、COVID-19は感染しやすくなるため、精神障害や神経障害を持つ患者に大きな問題を引き起こしています。例えば、2021年4月、血漿由来医薬品の主要なプロバイダーであるGrifolsは、NIHとNIAIDの両方と共同で、外来患者を対象とした抗SARS-CoV-2高静注用免疫グロブリンの分析調査に貢献しました。これは、予測期間中の市場成長に弾みをつけると予想されます。

主要企業は戦略的提携を採用し、競合を維持しようとしています。こうした取り組みには、M&A、提携、新製品開発などが含まれます。例えば、2022年3月にGrifolsのXEMBIFYが欧州で承認され、新規医薬品へのアクセスが増加しました。Grifolsは欧州での承認取得により、画期的な欧州IG製品群を拡大し、原発性・二次性免疫不全症に対する新たな重要な治療ソリューションを患者や医療従事者に提供できるようになりました。2021年2月、Pfizerは、重症炎症性脱髄性多発神経炎（CIDP）の成人患者を治療するための静注用免疫グロブリン製剤PANZYGAについて、米国FDAによる生物製剤追加承認申請（sBLA）の認可を取得しました。

静注用免疫グロブリン市場レポートハイライト

  • 低ガンマグロブリン血症用途セグメントは、2024年に第3位の収益シェアを占めました。これは、低ガンマグロブリン血症疾患の治療のための免疫グロブリン補充療法に対する需要が増加しているためであり、患者の意識レベルの上昇や疾患の発生件数の増加がその要因となっています。
  • 専門薬局は予測期間中に大幅な成長が見込まれます。病院は在宅治療の利便性を提供し、多くの患者にとって魅力的な選択肢となっています。これは、病院の大規模なネットワークと、病院薬局を通じて簡単にアクセスできる便利な製品群によるものです。さらに、病院は多くの患者に迅速な償還、治療、適切なケアを提供し、病院薬局を選択する患者の急増を可能にしています。
  • 専門薬局は自宅での治療を可能にするため、専門薬局流通チャネルセグメントは予測期間中に有利なCAGRで拡大すると予想されます。
  • 北米は、規制の整った医療システムの存在、対象人口の多さ、血漿タンパク製剤に関連する患者の意識の高さから、2024年の売上高で46.11%の最大シェアを占めました。
  • アジア太平洋のIVIG市場は、特に中国、インド、日本、オーストラリアなどの国々における免疫不全疾患の罹患率の大幅な増加に牽引され、急速に拡大しています。
  • インド、中国、南アフリカなどの国々は、医療施設の改善、医療費の増加、免疫不全疾患に関する国民の意識の高まりにより、予測期間中に大きな成長が見込まれています。
  • 川崎病セグメントは、予測期間中に市場で最も速い成長を示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 静注用免疫グロブリン市場の変数、動向、範囲

  • 親市場の展望
  • 補助市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場課題分析
  • 静注用免疫グロブリン分析ツール
    • ポーターの分析
    • PESTEL分析

第4章 静注用免疫グロブリン市場：用途別、推定・動向分析

  • 静注用免疫グロブリン市場：用途セグメントダッシュボード
  • 静注用免疫グロブリン市場：用途別変動分析、2024年と2030年
  • 免疫不全疾患
  • CIDP
  • 低ガンマグロブリン血症
  • 先天性エイズ
  • 慢性リンパ性白血病
  • 重症筋無力症
  • 多巣性運動神経障害
  • 免疫グロブリン
  • 川崎病
  • ギランバレー症候群
  • その他

第5章 静注用免疫グロブリン市場：流通チャネル別、推定・動向分析

  • 静注用免疫グロブリン市場：流通チャネルセグメントダッシュボード
  • 静注用免疫グロブリン市場：流通チャネル変動分析、2024年と2030年
  • 病院薬局
  • 専門薬局
  • その他

第6章 静注用免疫グロブリン市場：地域別、推定・動向分析

  • 静注用免疫グロブリン市場シェア、地域別、2024年と2030年、100万米ドル
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • 南アフリカ

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業市場シェア分析、2024年
  • 企業ヒートマップ分析、2024年
  • 企業プロファイル
    • BIoTest AG.
    • Baxter.
    • Octapharma AG
    • LFB
    • Grifols SA
    • CSL.
    • China Biologics Products Inc.
    • Kedrion.
    • BDI Pharma Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 4 Global Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 North America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 7 North America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Canada Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Canada Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 13 Mexico Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Europe Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 18 Germany Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 U.K. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 France Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 22 France Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Italy Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 24 Italy Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Spain Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Denmark Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 28 Denmark Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Sweden Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 30 Sweden Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Norway Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Norway Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 China Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 China Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 Japan Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 India Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 South Korea Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 South Korea Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Australia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Australia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Thailand Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Thailand Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Latin America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Latin America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Brazil Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Brazil Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 54 Argentina Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 South Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 63 UAE Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 Intravenous Immunoglobulin, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five forces Analysis
  • Fig. 15 Global Intravenous Immunoglobulin Market: By Application Movement Analysis
  • Fig. 16 Global Intravenous Immunoglobulin Market, for Immunodeficiency Diseases, 2018 - 2030 (USD Million)
  • Fig. 17 Global Intravenous Immunoglobulin Market, for CIDP, 2018 - 2030 (USD Million)
  • Fig. 18 Global Intravenous Immunoglobulin Market, for Hypogammaglobulinemia, 2018 - 2030 (USD Million)
  • Fig. 19 Global Intravenous Immunoglobulin Market, for Congenital AIDS, 2018 - 2030 (USD Million)
  • Fig. 20 Global Intravenous Immunoglobulin Market, for Chronic Lymphocytic Leukemia, 2018 - 2030 (USD Million)
  • Fig. 21 Global Intravenous Immunoglobulin Market, for Myasthenia Gravis, 2018 - 2030 (USD Million)
  • Fig. 22 Global Intravenous Immunoglobulin Market, for Multifocal Motor Neuropathy, 2018 - 2030 (USD Million)
  • Fig. 23 Global Intravenous Immunoglobulin Market, for ITP, 2018 - 2030 (USD Million)
  • Fig. 24 Global Intravenous Immunoglobulin Market, for Kawasaki Disease, 2018 - 2030 (USD Million)
  • Fig. 25 Global Intravenous Immunoglobulin Market, for Guillain-Barre Syndrome, 2018 - 2030 (USD Million)
  • Fig. 26 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 27 Global Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
  • Fig. 28 Global Intravenous Immunoglobulin Market, for Hospital Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Intravenous Immunoglobulin Market, for Specialty Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Marketplace: Key Takeaways Intravenous Immunoglobulin Market, Region 2018 - 2030 (USD Million)
  • Fig. 32 Regional Outlook, 2022 & 2030 Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 33 Global Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 34 North America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 35 US Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 62 Company/Competition Categorization
  • Fig. 63 Company Market Share Analysis, 2024
  • Fig. 64 Company Market Position Analysis, 2024
  • Fig. 65 Strategy Mapping
目次
Product Code: 978-1-68038-800-8

Intravenous Immunoglobulin Market Growth & Trends:

The global intravenous immunoglobulin market size is estimated to reach USD 21.05 billion by 2030, expanding at a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.

The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.

Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).

Intravenous Immunoglobulin Market Report Highlights:

  • The hypogammaglobulinemia application segment held the third-largest revenue share in 2024. This can be attributed to the increasing demand for immunoglobulin replacement therapies to treat hypogammaglobulinemia diseases, which is driven by rising awareness levels amongst patients and increasing incidences of the disease
  • Specialty pharmacy is expected to grow considerably over the forecast period. They offer the convenience of at-home treatment, making them an attractive option for many patients owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacie
  • The specialty pharmacy distribution channel segment is anticipated to expand at a lucrative CAGR during the forecast period as specialty pharmacies enable easy treatment at home
  • North America held the largest share of 46.11% in terms of revenue in 2024 due to the presence of a well-regulated healthcare system, the larger pool of target population, and high patient awareness pertinent to the plasma protein products
  • The IVIG market in Asia Pacific is expanding rapidly, driven by a significant increase in the incidence of immunodeficiency diseases, particularly in countries such as China, India, Japan, and Australia.
  • Countries such as India, China, and South Africa are expected to witness significant growth over the forecast period owing to improving healthcare facilities, rising healthcare expenditure, and growing public awareness regarding immune deficiency disorders
  • The Kawasaki disease segment is expected to exhibit the fastest growth in the market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Intravenous Immunoglobulin (IVIG) Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of immunodeficiency diseases
      • 3.3.1.2. Increasing adoption of immunoglobulin replacement therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Cost intensive nature of immunoglobulin replacement therapy
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
    • 3.3.3. Market Challenge Analysis
      • 3.3.3.1. Quality assurance and standardization-related challenges
      • 3.3.3.2. Limited scope for multiple evaluations
  • 3.4. Intravenous Immunoglobulin (IVIG) Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Intravenous Immunoglobulin (IVIG) Market: By Application Estimates & Trend Analysis

  • 4.1. Intravenous Immunoglobulin (IVIG) Market: Application Segment Dashboard
  • 4.2. Intravenous Immunoglobulin (IVIG) Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Immunodeficiency Diseases
    • 4.3.1. Immunodeficiency Diseases Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4. CIDP
    • 4.4.1. CIDP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Hypogammaglobulinemia
    • 4.5.1. Hypogammaglobulinemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Congenital AIDS
    • 4.6.1. Congenital AIDS Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Chronic Lymphocytic Leukemia
    • 4.7.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Myasthenia Gravis
    • 4.8.1. Myasthenia Gravis Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.9. Multifocal Motor Neuropathy
    • 4.9.1. Multifocal Motor Neuropathy Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.10. ITP
    • 4.10.1. ITP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.11. Kawasaki Disease
    • 4.11.1. Kawasaki Disease Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.12. Guillain-Barre Syndrome
    • 4.12.1. Guillain-Barre Syndrome Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.13. Others
    • 4.13.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Segment Dashboard
  • 5.2. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Hospital Pharmacies
    • 5.3.1. Hospital Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Specialty Pharmacies
    • 5.4.1. Specialty Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Immunoglobulin (IVIG) Market: Regional Estimates & Trend Analysis

  • 6.1. Intravenous Immunoglobulin (IVIG) Market Share, By Region, 2024 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018- 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Norway
      • 6.3.8.1. Norway Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Sweden Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Kuwait Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Africa
      • 6.6.5.1. South Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company Heat Map Analysis, 2024
  • 7.5. Company Profiles
    • 7.5.1. Biotest AG.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Baxter.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. Octapharma AG
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. LFB
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. Grifols SA
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. CSL.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. China Biologics Products Inc.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. Kedrion.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. BDI Pharma Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives